Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

July 31, 2016

Conditions
Cystic Fibrosis
Interventions
DRUG

Recombinant Human DNase (Pulmozyme)

2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months

DRUG

Placebos

2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Nationwide Children's Hospital

OTHER

NCT00179998 - Effectiveness of Pulmozyme in Infants With Cystic Fibrosis | Biotech Hunter | Biotech Hunter